[A new therapeutic approach to infertility in polycystic ovaries: pure FSH].
Current, improved understanding of the physiopathology of polycystic ovary syndrome offers the possibility of more suitable treatment. Formerly, objectives differed for a given patient: re-establish regular cycles using progestogens or estroprogestogens, reduce hirsutism with antiandrogens, trigger ovulation. Clomid is the inducer of choice, but setbacks occur. Injectable gonadotropins were, in principle, a contraindication due to the high incidence of excess stimulation and multiple pregnancy. The introduction of purified FSH offers another method of stimulation. Severe excess stimulation is eliminated with a suitable protocol involving administration of small doses. This offers hope, but as yet no large-scale trial has been published.
D002996:Clomiphene / Q000627:therapeutic use; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood / Q000627:therapeutic use*; D006062:Gonadotropins / Q000627:therapeutic use; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000097:blood; D010062:Ovulation Induction; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications* / Q000601:surgery; D013629:Tamoxifen / Q000627:therapeutic use
D006062:Gonadotropins; D013629:Tamoxifen; D002996:Clomiphene; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone
Une nouvelle approche thérapeutique de la stérilité dans les ovaires polykystiques: la FSH pure.